Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-na?ve, node-positive prostate cancer..     ///    TMPRSS2-ERG expression was analysed by PCR using a forward primer in TMPRSS2 exon 1 and a reverse primer in ERG exon 4.     ///    "To determine whether expression of androgen-regulated TMPRSS2-ERG predicts response to endocrine treatment in hormone-na?ve, node-positive PCa. "    ///    TMPRSS2-ERG was expressed in 59% of the 71 patients who could be analysed.     ///    Expression of TMPRSS2-ERG is frequent in lymph node metastases of patients with untreated PCa.     ///    Our results suggest that expression of TMPRSS2-ERG is not a candidate marker to select for metastatic PCa patients who will benefit more from endocrine treatment.. 